Elias Jabbour

In this discussion, Elias J. Jabbour, a Professor of Medicine at MD Anderson Cancer Center and expert on chronic myeloid leukemia (CML), dives into the intricacies of this disease affecting millions. He highlights the pivotal role of the Philadelphia chromosome in diagnosis and the life-saving impact of tyrosine kinase inhibitors like imatinib. Jabbour also addresses the challenges of medication compliance, therapy resistance, and the evolving criteria for stem cell transplants, painting a comprehensive picture of modern CML management.

Discussing the role of measurable residual disease in ALL treatment, advancements in TKIs for Ph+ ALL, medication-based treatments for high-risk patients, innovative strategies for Ph- leukemia patients, and the importance of achieving MRD negativity in leukemia therapy.